Combination of anti-EGFR and anti-HER2 antibodies: Hope in pancreatic cancer treatment;Combinaison d'anticorps anti-EGFR et anti-HER2: Un espoir dans le traitement du cancer du pancréas

Bulletin du Cancer

Volumn 94, Issue 10, 2007, Pages 860-862

  Larbouret, Christel ^a   Robert, Bruno ^a   Teulon, Isabelle ^a   Assénat, Eric ^b   Azria, David ^a,b   Pèlegrin, André ^a  

^a INSERM   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

Cancer; EGFR; HER2; Monoclonal antibodies; Pancreas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MATUZUMAB; MONOCLONAL ANTIBODY; TRASTUZUMAB;

CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL STRAIN BXPC3; DRUG EFFICACY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; PANCREAS CANCER; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 36248959267     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0487     Document Type: Short Survey

References (25)

1. Hill C, Doyon F. [The frequency of cancer in France : all ages and under age 15, mortality in 2003 and trends since 1968]. Bull Cancer 2007 ; 94 : 7-13.
2. Hammel P. [Pancreatic cancer : what is new in 2005?] Bull Cancer 2006 ; 93 : 67-72.
3. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002 ; 25 : 360-5.
4. Deberne M, Huguet F, Le Scodan R, Hammel P, Andre T. [Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006]. Bull Cancer 2007 ; 94 : 72-80.
5. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-13.
6. Rocha Lima CM, Green MR, Rotche R, Miller Jr. WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004 ; 22 : 3776-83.
7. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006 ; 24 : 3946-52.
8. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004 ; 363 : 1049-57.
9. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, et al. Epidermal growth factor receptor expression in human pancreatic cancer : significance for liver metastasis. Int J Mol Med 2003 ; 11 : 305-9.
10. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, et al. Assessment of HER-2 status in pancreatic adenocarcinoma : correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005 ; 29 : 1125-34.
11. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, et al. HER-2/neu expression in pancreatic adenocarcinoma : relation to tumor differentiation and survival. Pancreas 1997 ; 14 : 229-36.
12. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993 ; 24 : 1127-34.
13. Hynes NE, Lane HA. ERBB receptors and cancer : the complexity of targeted inhibitors. Nat Rev Cancer 2005 ; 5 : 341-54.
14. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003 ; 12 : 541-52.
15. Wang Z, Zhang L, Yeung TK, Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 1999 ; 10 : 1621-36.
16. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996 ; 271 : 5251-7.
17. Wilkinson JC, Staros JV. Effect of ErbB2 coexpression on the kinetic interactions of epidermal growth factor with its receptor in intact cells. Biochemistry 2002 ; 41 : 8-14.
18. Citri A, Yarden Y. EGF-ERBB signalling : towards the systems level. Nat Rev Mol Cell Biol 2006 ; 7 : 505-16.
19. Pèlegrin A, Xavier F, Barbet J, Bartholeyns J, Baty D, Buchegger F, et al. Immunociblage des tumeurs : situation et perspectives en 2000. Bull Cancer 2000 ; 87 : 777-91.
20. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004 ; 22 : 706-12.
21. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer : a multicenter phase II trial. J Clin Oncol 2004 ; 22 : 2610-6.
22. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007 ; 34 : 347-53.
23. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 7 2000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006 ; 94 : 1293-9.
24. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001 ; 61 : 8887-95.
25. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007 ; 13 : 3356-62.